Background: The interaction between the PI3K/AKT/mTOR and cyclin D–CDK4/6–INK4–Rb pathways has been reported to play a critical role in ER-driven breast cancer (BC). Furthermore, in preclinical ER+ BC models, the combination of ribociclib (LEE011; LEE), alpelisib (BYL719; BYL), and letrozole (LET) has recently shown enhanced activity vs each agent alone. A Phase Ib/II, 3-arm study is investigating the combination of LEE, BYL, and LET in pts with ER+ advanced (a)BC (CLEE011X2107; NCT01872260). Here, we report on safety, preliminary efficacy, and molecular analysis focusing on Arm (A)3 (LEE + BYL + LET) of Phase Ib. Methods: Postmenopausal women with ER+, HER2– aBC received a fixed dose of 2.5 mg LET QD (continuous) with escalating doses of either oral LEE QD (3-wks-on/1-wk-off) or BYL QD (continuous), or both, in 28-day cycles. The primary objective is to determine the MTD and/or RP2D of each combination by assessing DLTs in Cycle 1 using an adaptive Bayesian Logistic Regression Model with overdose control principle. Secondary objectives include safety, PK, and preliminary efficacy assessments. Potential biomarkers predictive of response were assessed by next-generation sequencing in all patients, and immunohistochemistry in available tumor samples. Results: As of Mar 2, 2015, 41 pts received LEE + LET (A1), 21 pts received BYL + LET (A2), and 36 pts received LEE (300–500 mg) + BYL (200–250 mg) + LET (A3). Here, we present results from A3. The number of prior endocrine regimens for advanced disease was: 0 (14 pts); 1–2 (14 pts); 3–4 (7 pts); ≥5 (1 pt); 33% of pts had previously received PI3K/AKT/mTOR inhibitors for aBC. Fifteen pts discontinued treatment: 7 (19%) due to PD and 8 (22%) due to AEs. The most frequent study drug-related AEs (all grade >35%) were: nausea (all grade, 44%; G3/4, 6%), hyperglycemia (44%; 17%), neutropenia (42%; 22%), and fatigue (36%; 11%). The median duration of exposure was 8 weeks; 9 (25%) pts received treatment for ≥4 cycles. Of 27 evaluable pts, 2 (7%) pts had PR, 4 (15%) pts had unconfirmed PR, 6 (22%) pts had SD, 6 (22%) pts had non-CR non-PD (NCRNPD), and 5 (19%) pts had PD as best overall response. One pt with PR was treated for 9 cycles, had 5 lines of prior therapy including a PI3K/AKT/mTOR inhibitor, and had alterations in PIK3R1 and CDK4. The other pt with PR was treated for >9 cycles, had 3 lines of prior therapy, and had alterations in PIK3CA and CCND1. In A1, an increase from baseline to C1D15 in pAKT and pS6(235) was observed in 5 and 3 pts, respectively; importantly, there was a more consistent reduction in Ki67 in A3 vs A1 or A2. Conclusions: LET + LEE + BYL (A3) has an acceptable safety profile and demonstrates preliminary clinical activity in heavily pretreated pts with ER+, HER2– aBC. Preliminary data suggest CDK4/6 pathway activation is associated with improved response to triplet therapy. Importantly, the pathway analysis reported is supportive of a mechanistic combination effect whereby inhibition of the three pathways provides a sustained downregulation of Ki67, potentially preventing a feedback mechanism and hence delaying progression through therapy. Future randomized studies will compare LET + LEE or BYL with LET + LEE + BYL. Citation Format: Juric D, Ismail-Khan R, Campone M, García-Estévez L, Becerra C, De Boer R, Hamilton E, Mayer IA, Hui R, Lathrop KI, Pagani O, Asano S, Bhansali SG, Zhang V, Hewes B, Munster P. Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-01.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.